SK bioscience will enter clinical trials of NBP2001 upon the IND approval from the Ministry of Foo...

- SK bioscience will submit an application for preliminary screening to the Korea Exchange (KRX) fo...

- The result of preclinical trial of a recombinant protein-based vaccine candidate, ‘NBP2001,’ is c...

- SK bioscience signs an agreement with Novavax to manufacture and supply COVID-19 vaccines global...

- NH Investment & Securities wereed as the lead underwriter and Korea Investment & Securit...

- Joint trilateral cooperation for stable production and global supply of COVID-19 vaccine - Reach...

- SKYCellflu ® Quadrivalent is now available to vaccinate everyone 6 months or older - The vaccin...

-The Bill & Melinda Gates Foundation provided 3.6 million USD to accelerate SK bioscience’s de...

- The IND amendment for a phase 2 study was filed last month - Enables access to the global pne...

- SK bioscience achieved expressing the COVID-19 vaccine candidate, securing recombinant proteins u...

- SK bioscience will initiate a project on the “Development of Candidate Substances for Recombinant...

- SKYZoster®’s cumulative sales expected to reach 100 billion KRW this year- SKYZoster’s market sha...